The clinical benefit of the decrease in opioid consumption has not been demonstrated.
EXPAREL is indicated for administration into the surgical site to produce postsurgical analgesia.
Important Safety Information
EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use
in patients younger than 18 years of age. Non-bupivacaine-based local anesthetics, including lidocaine, may
cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration
of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Formulations of
bupivacaine other than EXPAREL should not be administered within 96 hours following administration of EXPAREL.
Monitoring of cardiovascular and neurological status as well as vital signs should be performed during and after
injection of EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as
bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease.
Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at
a greater risk of developing toxic plasma concentrations. In clinical trials, the most common adverse reactions
(incidence ≥10%) following EXPAREL administration were nausea, constipation, and vomiting.
Please see brief summary of Prescribing Information on reverse side.
For more information, please visit
www.EXPAREL.com or call 1-855-RX-EXPAREL (793-9727).
Indication for EXPAREL
Supports Broad Use Across
Experience the impact:
Reduce the need for opioids while providing
long-lasting postsurgical pain control–all from a single dose.
Used in more than
1.5 MILLION PATIENTS since 2012
©2016 Pacira Pharmaceuticals, Inc., Parsippany, NJ 07054
Reference. Data on file. Parsippany, NJ: Pacira Pharmaceuticals, Inc.; September 2015.